Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na
Leukemia Research, 06/22/2012
Olnes MJ et al. – The preclinical results and responses of patients on a clinical trial warrant further investigation of ON 01910.Na as a potential novel targeted therapy for higher risk myelodysplastic syndromes (MDS) patients.



